6z6w: Difference between revisions
From Proteopedia
Jump to navigationJump to search
m Protected "6z6w" [edit=sysop:move=sysop] |
No edit summary |
||
| (3 intermediate revisions by the same user not shown) | |||
| Line 1: | Line 1: | ||
==Poliovirus type 3 (strain Saukett) stabilised virus-like particle (PV3 SC8) from a mammalian expression system.== | |||
<StructureSection load='6z6w' size='340' side='right'caption='[[6z6w]], [[Resolution|resolution]] 3.00Å' scene=''> | |||
== Structural highlights == | |||
<table><tr><td colspan='2'>[[6z6w]] is a 3 chain structure with sequence from [https://en.wikipedia.org/wiki/Human_poliovirus_3 Human poliovirus 3]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6Z6W OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=6Z6W FirstGlance]. <br> | |||
</td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">Electron Microscopy, [[Resolution|Resolution]] 3Å</td></tr> | |||
<tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=SPH:SPHINGOSINE'>SPH</scene></td></tr> | |||
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=6z6w FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6z6w OCA], [https://pdbe.org/6z6w PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=6z6w RCSB], [https://www.ebi.ac.uk/pdbsum/6z6w PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=6z6w ProSAT]</span></td></tr> | |||
</table> | |||
== Function == | |||
[https://www.uniprot.org/uniprot/Q84895_9ENTO Q84895_9ENTO] | |||
<div style="background-color:#fffaf0;"> | |||
== Publication Abstract from PubMed == | |||
Global vaccination programs using live-attenuated oral and inactivated polio vaccine (OPV and IPV) have almost eradicated poliovirus (PV) but these vaccines or their production pose significant risk in a polio-free world. Recombinant PV virus-like particles (VLPs), lacking the viral genome, represent safe next-generation vaccines, however their production requires optimisation. Here we present an efficient mammalian expression strategy producing good yields of wild-type PV VLPs for all three serotypes and a thermostabilised variant for PV3. Whilst the wild-type VLPs were predominantly in the non-native C-antigenic form, the thermostabilised PV3 VLPs adopted the native D-antigenic conformation eliciting neutralising antibody titres equivalent to the current IPV and were indistinguishable from natural empty particles by cryo-electron microscopy with a similar stabilising lipidic pocket-factor in the VP1 beta-barrel. This factor may not be available in alternative expression systems, which may require synthetic pocket-binding factors. VLPs equivalent to these mammalian expressed thermostabilized particles, represent safer non-infectious vaccine candidates for the post-eradication era. | |||
Mammalian expression of virus-like particles as a proof of principle for next generation polio vaccines.,Bahar MW, Porta C, Fox H, Macadam AJ, Fry EE, Stuart DI NPJ Vaccines. 2021 Jan 8;6(1):5. doi: 10.1038/s41541-020-00267-3. PMID:33420068<ref>PMID:33420068</ref> | |||
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | |||
[[Category: | </div> | ||
[[Category: | <div class="pdbe-citations 6z6w" style="background-color:#fffaf0;"></div> | ||
[[Category: | == References == | ||
[[Category: | <references/> | ||
[[Category: | __TOC__ | ||
</StructureSection> | |||
[[Category: Human poliovirus 3]] | |||
[[Category: Large Structures]] | |||
[[Category: Bahar MW]] | |||
[[Category: Fry EE]] | |||
[[Category: Porta C]] | |||
[[Category: Stuart DI]] | |||
Latest revision as of 08:53, 14 July 2024
Poliovirus type 3 (strain Saukett) stabilised virus-like particle (PV3 SC8) from a mammalian expression system.
| ||||||||||||
